Pharmacotheraphy for Alzheimer's disease.

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.

Original languageEnglish (US)
Pages (from-to)428-434
Number of pages7
JournalCurrent Neurology and Neuroscience Reports
Volume1
Issue number5
StatePublished - Sep 2001

Fingerprint

Alzheimer Disease
Amyloid Precursor Protein Secretases
Estrogen Replacement Therapy
Protein Precursors
Amyloid beta-Peptides
Cholinesterase Inhibitors
Publications
Immunization
Anti-Inflammatory Agents
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Pharmacotheraphy for Alzheimer's disease. / Knopman, David S.

In: Current Neurology and Neuroscience Reports, Vol. 1, No. 5, 09.2001, p. 428-434.

Research output: Contribution to journalArticle

@article{849c2c6494884d20b4c9216c8144a014,
title = "Pharmacotheraphy for Alzheimer's disease.",
abstract = "In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.",
author = "Knopman, {David S}",
year = "2001",
month = "9",
language = "English (US)",
volume = "1",
pages = "428--434",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Pharmacotheraphy for Alzheimer's disease.

AU - Knopman, David S

PY - 2001/9

Y1 - 2001/9

N2 - In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.

AB - In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0035468904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035468904&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 428

EP - 434

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 5

ER -